CN103119038B - 作为1-磷酸鞘氨醇1受体激动剂的4-(5-异噁唑基或5-吡唑基-1，2，4-噁二唑基-3-基)扁桃酰胺 - Google Patents

作为1-磷酸鞘氨醇1受体激动剂的4-(5-异噁唑基或5-吡唑基-1，2，4-噁二唑基-3-基)扁桃酰胺 Download PDF

Info

Publication number
CN103119038B
CN103119038B CN201180031281.1A CN201180031281A CN103119038B CN 103119038 B CN103119038 B CN 103119038B CN 201180031281 A CN201180031281 A CN 201180031281A CN 103119038 B CN103119038 B CN 103119038B
Authority
CN
China
Prior art keywords
phenyl
trifluoromethyl
acetamide
oxadiazole
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180031281.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103119038A (zh
Inventor
R.J.彻尼
Y.张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN103119038A publication Critical patent/CN103119038A/zh
Application granted granted Critical
Publication of CN103119038B publication Critical patent/CN103119038B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201180031281.1A 2010-04-23 2011-04-21 作为1-磷酸鞘氨醇1受体激动剂的4-(5-异噁唑基或5-吡唑基-1，2，4-噁二唑基-3-基)扁桃酰胺 Expired - Fee Related CN103119038B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32731510P 2010-04-23 2010-04-23
US61/327,315 2010-04-23
PCT/US2011/033364 WO2011133734A1 (en) 2010-04-23 2011-04-21 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists

Publications (2)

Publication Number Publication Date
CN103119038A CN103119038A (zh) 2013-05-22
CN103119038B true CN103119038B (zh) 2016-05-04

Family

ID=44069927

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180031281.1A Expired - Fee Related CN103119038B (zh) 2010-04-23 2011-04-21 作为1-磷酸鞘氨醇1受体激动剂的4-(5-异噁唑基或5-吡唑基-1，2，4-噁二唑基-3-基)扁桃酰胺

Country Status (6)

Country Link
US (1) US8835470B2 (https=)
EP (1) EP2560969B1 (https=)
JP (1) JP5735634B2 (https=)
CN (1) CN103119038B (https=)
ES (1) ES2548683T3 (https=)
WO (1) WO2011133734A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5788507B2 (ja) 2010-07-20 2015-09-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 置換３−フェニル−１，２，４−オキサジアゾール化合物
EP2619190B1 (en) 2010-09-24 2015-08-12 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
WO2012061459A1 (en) 2010-11-03 2012-05-10 Bristol-Myers Squibb Company Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases
TWI613182B (zh) 2013-02-21 2018-02-01 必治妥美雅史谷比公司 雙環化合物
AU2014257164B2 (en) 2013-04-22 2018-10-11 Abbvie Inc. Thiazoles and uses thereof
EP2878339A1 (en) * 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
TWI689487B (zh) 2014-08-20 2020-04-01 美商必治妥美雅史谷比公司 經取代雙環化合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062252A1 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
WO2008141731A2 (en) * 2007-05-18 2008-11-27 Bayer Healthcare Ag Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
CN101528726A (zh) * 2006-09-07 2009-09-09 埃科特莱茵药品有限公司 用作s1p1/edg1受体激动剂的噻吩衍生物

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
DE4102024A1 (de) 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US6069143A (en) 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
US20050070506A1 (en) 2002-01-18 2005-03-31 Doherty George A. Selective s1p1/edg1 receptor agonists
US7309721B2 (en) 2002-03-01 2007-12-18 Merck + Co., Inc. Aminoalkylphosphonates and related compounds as Edg receptor agonists
KR101025675B1 (ko) 2002-04-23 2011-03-30 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서 유용한 피롤로-트리아진 아닐린 화합물
JP2005533058A (ja) 2002-06-17 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
JP4516430B2 (ja) 2002-12-20 2010-08-04 メルク・シャープ・エンド・ドーム・コーポレイション １−（アミノ）インダン並びに（１，２−ジヒドロ−３−アミノ）−ベンゾフラン、ベンゾチオフェン及びインドール
MXPA05008531A (es) 2003-02-11 2005-11-17 Irm Llc Compuestos biciclicos novedosos y composiciones.
US20060252741A1 (en) 2003-05-15 2006-11-09 Colandrea Vincent J 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
CN1791592B (zh) 2003-05-19 2012-07-04 Irm责任有限公司 免疫抑制剂化合物和组合物
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
ES2558761T3 (es) 2003-05-19 2016-02-08 Novartis Ag Compuestos y composiciones inmunosupresores
BRPI0410439A (pt) 2003-05-19 2006-06-06 Irm Llc compostos e composições imunossupressoras
TW200505416A (en) 2003-08-12 2005-02-16 Mitsubishi Pharma Corp Bi-aryl compound having immunosuppressive activity
CN1859908A (zh) 2003-10-01 2006-11-08 默克公司 作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物
US7605171B2 (en) 2003-12-17 2009-10-20 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
AU2005299851B2 (en) 2004-10-22 2011-03-17 Merck Sharp & Dohme Corp. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
BRPI0609668A2 (pt) 2005-03-23 2011-10-18 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
CN101203512A (zh) 2005-04-22 2008-06-18 第一三共株式会社 杂环化合物
BRPI0612028A2 (pt) 2005-06-08 2010-10-13 Novartis Ag oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
EP1896446A1 (en) 2005-06-24 2008-03-12 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives
WO2007024922A1 (en) 2005-08-23 2007-03-01 Irm Llc Immunosuppressant compounds and compositions
EP1965807A4 (en) 2005-11-23 2010-10-27 Epix Delaware Inc S1P RECEPTOR MODULATING COMPOUNDS AND THEIR USE
TWI404706B (zh) 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
TW200806611A (en) 2006-02-09 2008-02-01 Daiichi Seiyaku Co Novel amidopropionic acid derivatives and medicine containing the same
JP2009530389A (ja) 2006-03-21 2009-08-27 エピックス デラウェア， インコーポレイテッド Ｓ１ｐ受容体調節化合物及びその使用
MX2008012738A (es) 2006-04-03 2009-02-06 Astellas Pharma Inc Heterocompuesto.
PE20080401A1 (es) * 2006-07-07 2008-06-23 Boehringer Ingelheim Int DERIVADOS DE HETEROARIL-FENIL SUSTITUIDOS COMO INHIBIDORES DE B-Raf-QUINASAS
US20080070866A1 (en) 2006-08-01 2008-03-20 Praecis Pharmaceuticals Incorporated Chemical compounds
JP2009269819A (ja) 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
TWI392671B (zh) 2006-09-07 2013-04-11 Actelion Pharmaceuticals Ltd 吡啶-４-基衍生物
AU2007292347A1 (en) 2006-09-07 2008-03-13 Allergan, Inc. Heteroaromatic compounds having sphingosine-1-phosphate (S1P) receptor agonist and/or antagonist biological activity
PE20080769A1 (es) 2006-09-08 2008-08-14 Novartis Ag Derivados de biaril-sulfonamida
ES2400163T3 (es) 2006-09-08 2013-04-08 Actelion Pharmaceuticals Ltd. Derivados de piridil-3-ilo como agentes de inmunomodulación
MX2009002915A (es) 2006-09-21 2009-03-31 Actelion Pharmaceuticals Ltd Derivados de fenilo y su uso como inmunomoduladores.
RU2009115963A (ru) 2006-09-29 2010-11-10 Новартис АГ (CH) Производные оксадиазола, обладающие противовоспалительными и иммунодепрессантными свойствами
CA2669102A1 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Tetralin analogs having sphingosine 1-phosphate agonist activity
SG177221A1 (en) * 2006-12-15 2012-01-30 Abbott Lab Novel oxadiazole compounds
CL2007003784A1 (es) 2006-12-21 2008-06-27 Abbott Lab Compuestos derivados de 1-amino-3-fenilciclopentano, que son agonistas o antagonistas de uno o mas receptores de la familia s1p; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar la esclerosis multiple, artritis reumato
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
GB0625648D0 (en) 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
WO2008091967A1 (en) 2007-01-26 2008-07-31 Smithkline Beecham Corporation Chemical compounds
PT2125797E (pt) 2007-03-16 2014-03-11 Actelion Pharmaceuticals Ltd Derivados aminopiridina como agonistas do receptor s1p1/edg1
EP2014653A1 (en) * 2007-06-15 2009-01-14 Bioprojet Novel dicarboxylic acid derivatives as S1P1 receptor agonists
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
RU2010114025A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) ПРИМЕНЕНИЕ ПЕПТИДА Gly-Arg-Gly-Asp-Asn-Pro В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА
ES2622423T3 (es) 2007-10-04 2017-07-06 Merck Serono S.A. Derivados de oxadiazol
AU2008306886B2 (en) 2007-10-04 2014-01-16 Merck Serono S.A. Oxadiazole diaryl compounds
RU2010121969A (ru) 2007-11-01 2011-12-10 Актелион Фармасьютиклз Лтд (Ch) Новые производные пиримидина
EP2222667B1 (en) * 2007-12-10 2013-02-20 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as agonists of s1p1/edg1
JP2012515787A (ja) * 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体
AR076984A1 (es) 2009-06-08 2011-07-20 Merck Serono Sa Derivados de pirazol oxadiazol
US8399451B2 (en) * 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062252A1 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
CN101528726A (zh) * 2006-09-07 2009-09-09 埃科特莱茵药品有限公司 用作s1p1/edg1受体激动剂的噻吩衍生物
WO2008141731A2 (en) * 2007-05-18 2008-11-27 Bayer Healthcare Ag Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

Also Published As

Publication number Publication date
EP2560969A1 (en) 2013-02-27
EP2560969B1 (en) 2015-08-12
JP5735634B2 (ja) 2015-06-17
US20130045964A1 (en) 2013-02-21
WO2011133734A1 (en) 2011-10-27
US8835470B2 (en) 2014-09-16
JP2013525369A (ja) 2013-06-20
ES2548683T3 (es) 2015-10-20
CN103119038A (zh) 2013-05-22

Similar Documents

Publication Publication Date Title
CN103119038B (zh) 作为1-磷酸鞘氨醇1受体激动剂的4-(5-异噁唑基或5-吡唑基-1，2，4-噁二唑基-3-基)扁桃酰胺
EP2592071B1 (en) Tricyclic heterocyclic compounds
EP2382212B1 (en) Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
EP2382211B1 (en) Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists
EP2389377B1 (en) Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
CN101562977A (zh) 新的二唑化合物
JP5602230B2 (ja) スフィンゴシン−１−リン酸受容体アゴニスト
CN103298807A (zh) 作为用于治疗自身免疫性疾病和血管疾病的s1p1激动剂的杂环化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160504

Termination date: 20170421